ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN OVERCOME THE POOR OUTCOME OF ADULT PH(+) ACUTE LYMPHOBLASTIC LEUKEMIA -- ON BEHALF OF TAIWAN SOCIETY OF BLOOD AND MARROW TRANSPLANTATION
Author(s): ,
Tran-Der Tan
Affiliations:
Hematology and Medical Oncology,Koo Foundation Sun Yat-Sen Cancer Center,Taipei,Taiwan, Province of China
,
Jih-Luh Tang
Affiliations:
Department of Internal Medicine,National Taiwan University Hospital,Taipei,Taiwan, Province of China
,
Ming Yao
Affiliations:
Department of Internal Medicine,National Taiwan University Hospital,Taipei,Taiwan, Province of China
,
Jyh-Pying Gau
Affiliations:
Department of Internal Medicine,Veteran General Hospital,Taipei,Taiwan, Province of China
,
Po-Nan Wang
Affiliations:
Department of Internal Medicine,Chang Gung Memorial Hospital,Taipei,Taiwan, Province of China
,
Su-Peng Yeh
Affiliations:
Department of Internal Medicine,China Medical University Hospital,Taichung,Taiwan, Province of China
,
Tsai-Yun Chen
Affiliations:
Department of Internal Medicine,National Cheng Kung University Hospital,Tainan,Taiwan, Province of China
,
Chieh-Lin Teng
Affiliations:
Department of Internal Medicine,Veteran General Hospital,Taichung,Taiwan, Province of China
Yi-Chang Liu
Affiliations:
Department of Internal Medicine,Kaohsiung Medical University Hospital,Kaohsiung,Taiwan, Province of China
EHA Library. Tan T. Jun 15, 2019; 267167; PS1550
Dr. Tran-Der Tan
Dr. Tran-Der Tan
Contributions
Abstract

Abstract: PS1550

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
Acute lymphoblastic leukemia included Ph(+), Ph-like, and others, and we know that the outcome of Ph(+) ALL was worse as compared with Ph(-). After the introduction of targeted tyrosine kinase inhibitor and allogeneic hematopoietic stem cell transplantation the overall survival improved in historical comparison.

Aims
We want to know in real world practice whether the outcome of Ph(+) ALL could be not inferior as compared with Ph(-) after combined TKI and chemotherapy induction therapy followed by allogeneic stem cell transplant.

Methods
This is a retrospective study from the data base of Taiwan Society of Blood and Marrow Transplantation (TSBMT) Registry and we compared the overall survival between Ph(+) and Ph(-) ALL.

Results
Between 2006 and 2018 we had 526 ALL patients underwent allogeneic hematopoietic stem cell transplantation, with median age of 31 (range 0.7 to 69) and male to female were 55% versus 45%. Pre-transplant disease status included 56% in CR1, 26% in CR2/CR3, 6% were induction failure, and 11% were relapsed patients. Ninty-three (18%) were Ph(+), and 433 (82%) were Ph(-). Seven patient received umbilical cord blood stem cells and 502 (95%) received peripheral blood stem cells, 37 (7%) received bone marrow stem cells, including 26 patients received both bone marrow and peripheral blood stem cells. The overall survival of all patients were 44% at 3 years and 40% at 5 years. For Ph(+) versus Ph(-) patients, 3-year OS were 49% versus 42% and 5-year OS were 49% versus 38%, respectively.

Conclusion
After the introduction of combination of targeted TKI plus chemotherap induction therapy followed by allogeneic stem cell transplantation, the outcome of Ph(+) ALL is not inferior to Ph(-) patients.

Session topic: 22. Stem cell transplantation - Clinical

Keyword(s): Acute lymphoblastic leukemia, Allogeneic hematopoietic stem cell transplant, Ph+ ALL

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies